Physician profile
Young Lu
NPI 1366861882
$7,917.41
in general payments reported to CMS, 2019-2025
12 companies · $1,380 in 2025
The $1,380 reported for 2025 was less than what a typical Orthopaedic Surgery of The Spine provider received nationally (typical 2025 total: $2,116).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $263 · 2021: $1,206 · 2022: $1,200 · 2023: $2,209 · 2024: $1,661 · 2025: $1,380.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,638 · Food and Beverage: $2,611.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,637.87 |
| Food and Beverage | $2,611.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,822.09 | 2021-2025 | Mazor X System, Aquamantys(Tm), Cd Horizon Spinal System |
| Stryker Corporation | $2,335.84 | 2020-2023 | Capri Corpectomy Cage System, Prolift |
| Nuvasive, INC. | $1,579.27 | 2022-2023 | Xlif |
| Globus Medical, INC. | $402.44 | 2023-2025 | Xlif, Mars, Mars 3v/3vl |
| Seaspine Orthopedics Corporation | $203.54 | 2020 | |
| Trackx Technology, INC. | $156.31 | 2024-2025 | |
| Sanara Medtech INC. | $126.87 | 2025 | Celleraterx |
| Galderma Laboratories, L.P. | $125.37 | 2025 | Nemluvio |
| Orthofix Medical, INC. | $111.28 | 2024 | Spinal-Stim |
| Cerapedics INC. | $21.44 | 2024 | I-Factor Peptide Enhanced Bone Graft |
| Bioventus LLC | $18.57 | 2024 | Bonescalpel & Sonicone (O.R.) |
| Smith+Nephew, INC. | $14.39 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Young Lu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.